Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (Review)

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2051-2060

  Liang, Chen ^a   Li, Ying Yi ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Cytokine; Hormone; Inhibitor; MicroRNA; Phosphoinositide 3 kinase like protein kinase; Pim kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE COMPETITIVE INHIBITOR; ADENOSINE TRIPHOSPHATE MIMETIC INHIBITOR; ANTINEOPLASTIC AGENT; ESTROGEN; INECALCITOL; MICRORNA; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 1 INHIBITOR; UNCLASSIFIED DRUG; CYTOKINE; HORMONE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; CANCER PATIENT; CANCER THERAPY; CELL CYCLE REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PIM 1 GENE; PROTO ONCOGENE; REVIEW; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA INTERFERENCE;

EID: 84899697597     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2139     Document Type: Review

References (97)

1. Cuypers HT, Selten G, Quint W, et al : Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37: 141-150, 1984. (Pubitemid 14079845)
2. Bachmann M and Möröy T: The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726-730, 2005. (Pubitemid 40202995)
3. Mikkers H, Nawijn M, Allen J, et al: Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24: 6104-6115, 2004. (Pubitemid 38787993)
4. Selten G, Cuypers HT, Boelens W, et al: The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases. Cell 46: 603-611, 1986. (Pubitemid 16022415)
5. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ and Arthur JS: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 7: 1, 2006.
6. Saris CJ, Domen J and Berns A: The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10: 655-664, 1991. (Pubitemid 21905520)
7. Morishita D, Katayama R, Sekimizu K, Tsuruo T and Fujita N: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 68: 5076-5085, 2008.
8. Reeves R, Spies GA, Kiefer M, Barr PJ and Power M: Primary structure of the putative human oncogene, pim-1. Gene 90: 303-307, 1990. (Pubitemid 20261714)
9. Qian KC, Wang L, Hickey ER, et al: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130-6137, 2005. (Pubitemid 40280098)
10. Nawijn MC, Alendar A and Berns A: For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11: 23-34, 2011.
11. Bullock AN, Debreczeni J, Amos AL, Knapp S and Turk BE: Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280: 41675-41682, 2005. (Pubitemid 43000572)
12. Mukaida N, Wang YY and Li YY: Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci 102: 1437-1442, 2011.
13. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A and Kuchino Y: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659-18666, 1999.
14. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J and Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45-55, 2002. (Pubitemid 35335911)
15. Bachmann M, Hennemann H, Xing PX, Hoffmann I and Möröy T: The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319-48328, 2004. (Pubitemid 39540988)
16. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I and Möröy T: The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 38: 430-443, 2006. (Pubitemid 41821890)
17. Nosaka T and Kitamura T: Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp Hematol 30: 697-702, 2002. (Pubitemid 34831689)
18. Brault L, Gasser C, Bracher F, Huber K, Knapp S and Schwaller J: PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004-1015, 2010.
19. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
20. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
21. Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394, 2006. (Pubitemid 44289189)
22. Thomas M, Lange-Grünweller K, Weirauch U, et al : The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31: 918-928, 2012.
23. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
24. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105, 2007. (Pubitemid 46991392)
25. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005. (Pubitemid 41377683)
26. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002. (Pubitemid 35403967)
27. Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
28. Birg F, Courcoul M, Rosnet O, et al : Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 80: 2584-2593, 1992.
29. Nakao M, Yokota S, Iwai T, et al: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918, 1996. (Pubitemid 27019637)
30. Yokota S, Kiyoi H, Nakao M, et al: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11: 1605-1609, 1997. (Pubitemid 27458595)
31. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335, 2002. (Pubitemid 34627197)
32. Kim KT, Baird K, Ahn JY, et al: Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759-1767, 2005. (Pubitemid 40223700)
33. Kim KT, Baird K, Davis S, et al: Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol 138: 603-615, 2007. (Pubitemid 47206718)
34. Kim KT, Carroll AP, Mashkani B, Cairns MJ, Small D and Scott RJ: MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. PLoS One 7: e44546, 2012.
35. Mizuki M, Fenski R, Halfter H, et al: Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: 3907-3914, 2000.
36. Tse KF, Mukherjee G and Small D: Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14: 1766-1776, 2000.
37. Hayakawa F, Towatari M, Kiyoi H, et al: Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19: 624-631, 2000. (Pubitemid 30102913)
38. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL and Kitamura T: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754-4765, 1999. (Pubitemid 29415529)
39. Rayner KJ, Suárez Y, Dávalos A, et al: MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570-1573, 2010.
40. Tian Z, Zhao JJ, Tai YT, et al : Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 120: 3958-3967, 2012.
41. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224, 2011.
42. Chen JF, Mandel EM, Thomson JM, et al : The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38: 228-233, 2006. (Pubitemid 43177239)
43. Zhao Y, Ransom JF, Li A, et al: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129: 303-317, 2007. (Pubitemid 46574975)
44. Katakami N, Kaneto H, Hao H, et al: Role of pim-1 in smooth muscle cell proliferation. J Biol Chem 279: 54742-54749, 2004. (Pubitemid 40053219)
45. Chen J, Yin H, Jiang Y, et al: Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation. Arterioscler Thromb Vasc Biol 31: 368-375, 2011.
46. Katare RG, Caporali A, Oikawa A, Meloni M, Emanueli C and Madeddu P: Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail 3: 294-305, 2010.
47. Katare R, Caporali A, Zentilin L, et al: Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 108: 1238-1251, 2011.
48. Mishima T, Mizuguchi Y, Kawahigashi Y, Takizawa T and Takizawa T: RT-PCR-based analysis of microRNA (miR-1 and -124) expression in mouse CNS. Brain Res 1131: 37-43, 2007. (Pubitemid 46053907)
49. Sevignani C, Calin GA, Nnadi SC, et al: MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA 104: 8017-8022, 2007. (Pubitemid 47185868)
50. Nasser MW, Datta J, Nuovo G, et al: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405, 2008.
51. Jin Y, Tong DY, Chen JN, et al: Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PloS One 7: e48575, 2012.
52. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA and Skorski T: Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99: 4531-4539, 2002. (Pubitemid 34627224)
53. Eiring AM, Harb JG, Neviani P, et al: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140: 652-665, 2010.
54. Kulshreshtha R, Ferracin M, Wojcik SE, et al: A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867, 2007.
55. Camps C, Buffa FM, Colella S, et al: hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348, 2008. (Pubitemid 351413913)
56. Huang X, Ding L, Bennewith KL, et al: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867, 2009.
57. Kelsey JL: Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15: 256-263, 1993.
58. Horimoto Y, Hartman J, Millour J, et al: ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am J Pathol 179: 1148-1156, 2011.
59. Malinen M, Jääskeläinen T, Pelkonen M, et al: Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol Cell Endocrinol 365: 270-276, 2013.
60. Dumas de la Roque E, Savineau JP and Bonnet S: Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 126: 186-199, 2010.
61. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A and Bonnet S: Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 301: H1798-H1809, 2011.
62. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001. (Pubitemid 32801464)
63. Guzey M, Kitada S and Reed JC: Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1: 667-677, 2002.
64. Okamoto R, Delansorne R, Wakimoto N, et al: Inecalcitol, an analog of 1α,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 130: 2464-2473, 2012.
65. Ha S, Iqbal NJ, Mita P, et al: Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 32: 3992-4000, 2013.
66. Maier CJ, Maier RH, Rid R, et al: PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC Mol Biol 13: 18, 2012.
67. Shand RL and Gelmann EP: Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 16: 123-131, 2006. (Pubitemid 43791779)
68. Roach M III: Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer: Mar 3, 2014 (Epub ahead of print).
69. Carson JP, Kulik G and Weber MJ: Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B. Cancer Res 59: 1449-1453, 1999. (Pubitemid 29160109)
70. Sun A, Tang J, Hong Y, et al: Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Prostate 68: 453-461, 2008. (Pubitemid 351342650)
71. Kumar JK, Ping RY, Teong HF, Goh S and Clément MV: Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells. Int J Biochem Cell Biol 43: 594-603, 2011.
72. Min X, Tang J, Wang Y, et al: PI3K-like kinases restrain Pim gene expression in endothelial cells. J Huazhong Univ Sci Technolog Med Sci 32: 17-23, 2012.
73. Muraski JA, Rota M, Misao Y, et al: Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467-1475, 2007. (Pubitemid 350224243)
74. Zippo A, De Robertis A, Bardelli M, Galvagni F and Oliviero S: Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103: 4536-4544, 2004. (Pubitemid 38745981)
75. Stout BA, Bates ME, Liu LY, Farrington NN and Bertics PJ: IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils. J Immunol 173: 6409-6417, 2004. (Pubitemid 39487801)
76. Willert M, Augstein A, Poitz DM, Schmeisser A, Strasser RH and Braun-Dullaeus RC: Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation. Basic Res Cardiol 105: 267-277, 2010.
77. Block KM, Hanke NT, Maine EA and Baker AF: IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas 41: 773-781, 2012.
78. Jacobs MD, Black J, Futer O, et al: Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280: 13728-13734, 2005. (Pubitemid 40517268)
79. Gavara L, Suchaud V, Nauton L, Théry V, Anizon F and Moreau P: Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors. Bioorg Med Chem Lett 23: 2298-2301, 2013.
80. Blanco-Aparicio C and Carnero A: Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 85: 629-643, 2013.
81. Mumenthaler SM, Ng PY, Hodge A, et al : Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8: 2882-2893, 2009.
82. Chen LS, Redkar S, Taverna P, Cortes JE and Gandhi V: Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118: 693-702, 2011.
83. Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ and Gandhi V: Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120: 3491-3500, 2012.
84. Batra V, Maris JM, Kang MH, et al: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 59: 749-752, 2012.
85. Chen LS, Redkar S, Bearss D, Wierda WG and Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114: 4150-4157, 2009.
86. Chang M, Kanwar N, Feng E, et al: PIM kinase inhibitors down-regulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther 9: 2478-2487, 2010.
87. Siu A, Virtanen C and Jongstra J: PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget 2: 1134-1144, 2011.
88. Xie Y, Burcu M, Linn DE, Qiu Y and Baer MR: Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol 78: 310-318, 2010.
89. Natarajan K, Bhullar J, Shukla S, et al: The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol 85: 514-524, 2013.
90. Kelly KR, Espitia CM, Taverna P, et al: Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol 156: 129-132, 2012.
91. Pogacic V, Bullock AN, Fedorov O, et al: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 67: 6916-6924, 2007. (Pubitemid 47105539)
92. Holder S, Zemskova M, Zhang C, et al: Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6: 163-172, 2007. (Pubitemid 46206679)
93. Jie W, He QY, Luo BT, et al: Inhibition of Pim-1 attenuates the proliferation and migration in nasopharyngeal carcinoma cells. Asian Pac J Trop Med 5: 645-650, 2012.
94. Akué-Gédu R, Rossignol E, Azzaro S, et al: Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 52: 6369-6381, 2009.
95. Santio NM, Vahakoski RL, Rainio EM, et al: Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer 9: 279, 2010.
96. Mori M, Tintori C, Christopher RS, et al: A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors. ChemMedChem 8: 484-496, 2013.
97. Grundler R, Brault L, Gasser C, et al: Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 206: 1957-1970, 2009.